Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Profit After Tax: 2019-2024

Historic Profit After Tax for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to -$223.9 million.

  • Kymera Therapeutics' Profit After Tax fell 31.51% to -$82.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$295.1 million, marking a year-over-year decrease of 76.22%. This contributed to the annual value of -$223.9 million for FY2024, which is 52.32% down from last year.
  • As of FY2024, Kymera Therapeutics' Profit After Tax stood at -$223.9 million, which was down 52.32% from -$147.0 million recorded in FY2023.
  • In the past 5 years, Kymera Therapeutics' Profit After Tax registered a high of -$45.6 million during FY2020, and its lowest value of -$223.9 million during FY2024.
  • Its 3-year average for Profit After Tax is -$175.2 million, with a median of -$154.8 million in 2022.
  • Its Profit After Tax has fluctuated over the past 5 years, first tumbled by 119.81% in 2021, then rose by 5.07% in 2023.
  • Over the past 5 years, Kymera Therapeutics' Profit After Tax (Yearly) stood at -$45.6 million in 2020, then slumped by 119.81% to -$100.2 million in 2021, then plummeted by 54.47% to -$154.8 million in 2022, then climbed by 5.07% to -$147.0 million in 2023, then tumbled by 52.32% to -$223.9 million in 2024.